Star Imaging and Path Lab Ltd. (STARIMAGIN): Star Imaging and Path Lab Share Price Rises 10% as Micro Cap Stock Turns Top Gainer

Star Imaging and Path Lab Ltd. rose to Rs 89.76, up 10% today, taking its market capitalisation to Rs 143.21 crore and placing the micro cap healthcare stock among the session’s top gainers.

Star Imaging and Path Lab Share Price moved to Rs 89.76 on 11 August 2026, up 10% from the previous close of Rs 81.60, lifting the company’s market capitalisation to Rs 143.21 crore. For traders scanning Stocks in News and Top Gainers Today, that puts this micro cap healthcare name firmly on the radar in today’s Share Market Today action.

The verified data confirms a sharp same-day price rise in Star Imaging and Path Lab Ltd., with the stock opening at Rs 86, holding the day’s low at Rs 86 and then rising to an intraday high of Rs 89.76, which also matched the current traded price at the time of this update. Total volume stood at 18,000 shares on the BSE, with turnover of Rs 0.16 crore. The move qualifies under the stock’s Micro Cap market-cap category, which is why the price action is relevant in the first place.

What the supplied data does not establish is a company-specific catalyst. So, while Star Imaging and Path Lab Stock News today clearly confirms the share price gain and the stock’s trending status, the data set supports the price event itself rather than a reason behind it. Investors tracking Star Imaging and Path Lab Share Price Today may therefore focus on three things next: whether the stock can hold near the day’s high, how its valuation compares with healthcare peers, and whether profitability metrics such as ROE of 34.28% and ROCE of 23.64% continue to justify investor attention. At Univest, that combination of price action and fundamentals is what makes this move worth analysing beyond a simple market update.

Star Imaging and Path Lab Ltd. (STARIMAGIN) Share Price Today: Price Action Analysis

Star Imaging and Path Lab Ltd. (STARIMAGIN) traded at Rs 89.76. versus the previous close of Rs 81.6, a rise of 10%. The stock opened at Rs 86, reached Rs 89.76, touched Rs 86. Reported volume was 18,000.

Star Imaging and Path Lab Ltd. (STARIMAGIN) Fundamental Analysis

Star Imaging and Path Lab Ltd. was valued at a P/E ratio of 7.37x, a P/B ratio of 1.23x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 34.28% and ROCE of 23.64%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 11.07, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Star Imaging and Path Lab Fundamental Analysis shows a small listed healthcare company with modest headline valuation multiples but strong reported return ratios. That mix helps explain why the stock can attract investor attention after a price rise even when the data does not identify a fresh corporate catalyst.

The company’s market capitalisation stands at Rs 143.21 crore, placing it in the micro cap segment. Its price-to-earnings ratio is 7.37, while the price-to-book ratio is 1.23. Those two figures are important because they show Star Imaging and Path Lab Share Price is being valued at a much lower earnings multiple than many listed peers in the same Hospital & Healthcare Services industry. On book value too, the stock trades at a relatively restrained multiple versus much of the broader peer set discussed later.

Profitability metrics are stronger than the headline market cap may suggest. Return on equity is 34.28%, while return on capital employed is 23.64%. ROE measures the return generated on shareholder equity, and a 34.28% reading is a strong figure in absolute terms. ROCE of 23.64% also indicates the business has delivered solid returns on capital employed. Together, these numbers give Star Imaging and Path Lab Stock Analysis a better quality angle than the size of the company alone would imply.

EPS is Rs 11.07, which means the earnings attributable to each share are meaningful relative to the current price of Rs 89.76. That relationship is one reason the P/E multiple remains at 7.37. Dividend yield is 0, which indicates the current or historical payout relative to market price is nil in the supplied data. For investors focused on income, that means the present investment case is tied more to business returns and valuation than to cash distributions.

Another useful way to read the numbers is to combine them rather than viewing them in isolation. A low P/E can sometimes reflect weak profitability, but here the supplied ROE and ROCE are both healthy. A low P/B can also sometimes sit alongside stressed returns, but again that is not what the current data shows. Univest therefore sees a stock where valuation multiples look compressed relative to industry benchmarks, while business return ratios remain competitive. That does not amount to a recommendation, but it does explain why Star Imaging and Path Lab Share Price Rise is drawing attention after today’s move. The next question is whether this relative attractiveness still holds up against the broader healthcare industry context and peer group.

Sector and Industry Context

Star Imaging and Path Lab Ltd. (STARIMAGIN) is classified under sector: Healthcare and industry: Hospital & Healthcare Services.

Star Imaging and Path Lab Ltd. (STARIMAGIN) has a P/E ratio of 7.37x, which is below the benchmark median of 27.3x, a difference of -73%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Star Imaging and Path Lab Ltd. (STARIMAGIN) has a ROE of 34.28%, which is above the benchmark median of 14.66%, a difference of +133.83%. Star Imaging and Path Lab Ltd. (STARIMAGIN) has a ROCE of 23.64%, which is above the benchmark median of 18.85%, a difference of +25.41%.

Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Star Imaging and Path Lab operates in Healthcare, specifically Hospital & Healthcare Services, and the sector snapshot shows the company sits at the low end of the industry valuation range while posting returns that compare favourably with benchmark medians. That combination is central to understanding today’s investor focus.

The benchmark scope is the same industry, covering 40 companies in Hospital & Healthcare Services. Within that group, Star Imaging and Path Lab’s P/E of 7.37 is below the industry median P/E of 27.3 and far below the average P/E of 218.45. It is also equal to the benchmark minimum of 7.37, while the maximum reaches 2992.36 across 33 companies with available P/E data. On that specific measure, Star Imaging and Path Lab Share Price looks positioned at the cheapest end of the disclosed earnings-multiple range.

The price-to-book comparison also leans lower. The company’s P/B is 1.23, against a sector median of 2.06 and an average of 2.75 across 40 companies. The range runs from -9.79 to 15.59, and Star Imaging and Path Lab sits below both the median and the average. In plain terms, the market is not placing an aggressive balance-sheet multiple on this stock versus the wider industry sample.

On profitability, the comparison is more balanced but still constructive. The company’s ROE of 34.28% is comfortably above the industry median of 14.66%, though slightly below the average of 36.33%. Its ROCE of 23.64% is above both the median ROCE of 18.85% and the average of 21.42%. That matters because it suggests the lower valuation is not being explained by obviously weak return metrics in the supplied data.

Size also adds perspective. The company’s market capitalisation of Rs 143.21 crore is above the industry median market cap of Rs 103.36 crore but well below the average of Rs 448.99 crore. The range stretches from Rs 4.86 crore to Rs 2,601.85 crore. So, while Star Imaging and Path Lab is small in sector terms, it is not the smallest player in the benchmark universe. At Univest, the industry snapshot suggests a stock that is smaller and lower valued than many peers, but still posting return ratios that are competitive within the healthcare pack.

Peer Comparison

Star Imaging and Path Lab Ltd. (STARIMAGIN) has a P/E ratio of 7.37x compared with the displayed peer median of 34.14x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 34.28% compares with a peer median of 5.19% across the companies shown in the table. ROCE stood at 23.64% versus the displayed peer median of 22.94%, providing a capital-efficiency comparison. Star Imaging and Path Lab Ltd. (STARIMAGIN) has a market capitalisation of Rs 143.21 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Peer comparison shows Star Imaging and Path Lab sits at a much smaller market capitalisation than the named listed peers, but its valuation and profitability mix stands out in specific ways. The company’s P/E of 7.37 is below all the major peers listed in the supplied comparison set, including Dr Agarwals Eye Hospital at 34.14, KMC Speciality Hospitals at 40.67, Krsnaa Diagnostics at 17.92, Shalby at 15.49 and GPT Healthcare at 27.3.

That makes Star Imaging and Path Lab Share Price notable from a relative valuation angle. Even Shalby, which has one of the lower peer P/E readings in the group, trades at 15.49, still well above 7.37. On P/B, Star Imaging and Path Lab at 1.23 is below Dr Agarwals Eye Hospital at 7.04, KMC Speciality Hospitals at 9.03, Krsnaa Diagnostics at 1.85, SURAKSHA Diagnostic at 5.54 and GPT Healthcare at 4.57. Only Shalby comes closer at 1.4, but Star Imaging and Path Lab still trades below that level.

Profitability gives a more nuanced picture. ROE at 34.28% is stronger than Dr Agarwals Eye Hospital at -2.6%, KMC Speciality Hospitals at 22.42%, Shalby at 5.19%, SURAKSHA Diagnostic at 13.93%, GPT Healthcare at 33.06%, Unihealth Hospitals at 29.75% and Gujarat Kidney N Sup Sp L at 26.56%. It remains below the exceptionally high ROE readings of Gaudium IVF at 94.99% and KRM Ayurveda at 90.82%.

On ROCE, Star Imaging and Path Lab at 23.64% is ahead of Dr Agarwals Eye Hospital at 16.92%, Shalby at 6.85%, Unihealth Hospitals at 20.33% and SURAKSHA Diagnostic at 22.94%, but below KMC Speciality Hospitals at 25.85%, GPT Healthcare at 25.56%, Gujarat Kidney at 36.31%, KRM Ayurveda at 37.67%, Gaudium IVF at 82.39% and Krsnaa Diagnostics at 129.09%.

The market-cap gap is substantial. Star Imaging and Path Lab is valued at Rs 143.21 crore, while the peers named here range from Rs 701.18 crore for KRM Ayurveda to Rs 2,601.85 crore for Dr Agarwals Eye Hospital. That means investors are looking at a far smaller company, but one whose reported P/E, P/B and return profile give it a distinct relative position within the healthcare peer basket. Univest views that contrast as one reason the stock’s price rise is being watched closely today.

Why Investors Are Watching Star Imaging and Path Lab

Investors are watching this stock because today’s move combines a clear intraday price gain with valuation metrics that look notably lower than the broader industry benchmark. Even without a verified company-specific trigger in the supplied data, the mix of price action, profitability and peer valuation is enough to keep the stock in focus.

• Price action: Star Imaging and Path Lab Share Price rose 10% to Rs 89.76 from Rs 81.60, with the stock holding above its Rs 86 open and touching the day’s high at the latest price.
• Trading activity: Total volume was 18,000 shares on BSE, with turnover of Rs 0.16 crore, making this a visible move within a micro cap stock.
• Valuation context: The company trades at 7.37 times earnings and 1.23 times book value, both below the same-industry median and average benchmarks.
• Profitability profile: ROE of 34.28% and ROCE of 23.64% compare well against benchmark medians, which strengthens the fundamental context around the move.
• Sector positioning: The stock operates in Healthcare and Hospital & Healthcare Services, where several larger peers trade at meaningfully higher multiples.

What investors may monitor next is whether Star Imaging and Path Lab Share Price can sustain levels near the day’s high, whether the valuation gap with peers continues to attract attention, and whether future company updates align with the strong return ratios currently visible in the supplied data. That is the practical reason this stock remains on today’s market watchlists at Univest.

About Star Imaging and Path Lab

Star Imaging and Path Lab Ltd. is part of the Healthcare sector and falls within the Hospital & Healthcare Services industry. The available data places the company in a healthcare services segment alongside listed peers such as diagnostics, speciality hospitals and other patient-service businesses that operate within the broader medical services ecosystem.

From a market perspective, the company is still a micro cap name with a market capitalisation of Rs 143.21 crore, which means it is much smaller than several established listed peers in the same industry. Even so, its industry classification matters because Hospital & Healthcare Services is a segment where investors often compare companies on valuation multiples, profitability metrics and relative scale rather than on a single day’s price movement alone.

That is also why Star Imaging and Path Lab Share Price attracts attention during strong trading sessions. In the absence of a detailed supplied company description, the most reliable context comes from its sector and industry placement: a healthcare-services business being assessed within a 40-company same-industry benchmark. Within that universe, the company stands out for combining a lower P/E and P/B with healthy ROE and ROCE figures. For readers following Star Imaging and Path Lab Latest News, that industry context is essential to understanding how the market is currently pricing the stock.

Track Star Imaging and Path Lab Share Price on Univest

Use Star Imaging and Path Lab Ltd. (STARIMAGIN) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Readers tracking Star Imaging and Path Lab Share Price can use Univest to follow live market moves, stock performance trends and deeper financial context in one place. Alongside Star Imaging and Path Lab Share Price Today, users can monitor market capitalisation, 52-week levels, valuation ratios such as P/E and P/B, profitability indicators like ROE and ROCE, and broader Stock News coverage.

Univest also helps investors compare sector benchmarks, review peer positioning in Healthcare and Hospital & Healthcare Services, and keep track of intraday Share Price updates as market conditions change. For those watching STARIMAGIN after today’s price rise, that makes it easier to place a single-session move within a wider stock analysis and market update framework.

Frequently Asked Questions

Why is Star Imaging and Path Lab Share Price rising today?

Ans. Star Imaging and Path Lab Share Price rose 10% today from Rs 81.60 to Rs 89.76. The supplied data confirms the price rise, higher intraday range and BSE trading activity, but it does not identify a company-specific catalyst behind the.

What is Star Imaging and Path Lab Share Price Today?

Ans. Star Imaging and Path Lab Share Price Today was Rs 89.76 at the supplied update time on 11 August 2026 at 11:17:10 AM IST. That level matched the day’s high and reflected a 10% gain over the previous close.

How much did STARIMAGIN gain in today’s session?

Ans. STARIMAGIN gained Rs 8.16 in absolute terms and 10% in percentage terms during the session covered by this update. The stock moved from a previous close of Rs 81.60 to a current price of Rs 89.76.

What does today’s intraday price action show?

Ans. The stock opened at Rs 86, traded at a low of Rs 86 and then rose to Rs 89.76, which was also the day’s high. That suggests buying support through the session rather than only a brief opening move.

What was the traded volume in Star Imaging and Path Lab today?

Ans. The supplied data shows current volume, BSE volume and total volume of 18,000 shares. Turnover was Rs 0.16 crore on BSE, which is consistent with the company’s micro cap size and today’s visible share price gain.

What is the market capitalisation of Star Imaging and Path Lab Ltd.?

Ans. Star Imaging and Path Lab Ltd. had a market capitalisation of Rs 143.21 crore in this update. That places the company in the Micro Cap category, which is relevant when assessing today’s top gainer status.

Is Star Imaging and Path Lab expensive based on P/E and P/B?

Ans. The stock’s P/E is 7.37 and P/B is 1.23. Both are below the same-industry median values of 27.3 and 2.06 respectively, suggesting the stock trades at lower valuation multiples than the benchmark group.

How strong are the company’s profitability metrics?

Ans. The company reported ROE of 34.28% and ROCE of 23.64%. ROE is above the industry median of 14.66%, while ROCE is above the median of 18.85%, giving the stock a solid reported profitability profile.

What do EPS and dividend yield indicate here?

Ans. EPS stands at Rs 11.07, showing the earnings attributable to each share in the supplied data. Dividend yield is 0, indicating no current or historical yield contribution is reflected in this market snapshot.

Which sector does Star Imaging and Path Lab belong to?

Ans. Star Imaging and Path Lab belongs to the Healthcare sector and the Hospital & Healthcare Services industry. Its sector benchmark covers 40 same-industry companies, offering useful context for valuation, profitability and peer comparison.